Click here to get full coverage on Five county athletes among HCC Athletes of the Year - Hamilton County Reporter

Five county athletes among HCC Athletes of the Year  Hamilton County Reporter

Five county athletes among HCC Athletes of the Year - Hamilton County Reporter

Click here to get full coverage on Nina Niu Sanford: Multidisciplinary and International HCC Tumor Board at GI ASCO 2026 - Oncodaily

Nina Niu Sanford: Multidisciplinary and International HCC Tumor Board at GI ASCO 2026  Oncodaily

Nina Niu Sanford: Multidisciplinary and International HCC Tumor Board at GI ASCO 2026 - Oncodaily

Click here to get full coverage on HCC announces new university transfer agreements - Smoky Mountain News

HCC announces new university transfer agreements  Smoky Mountain News

HCC announces new university transfer agreements - Smoky Mountain News

Click here to get full coverage on Early voting opens in Houston’s At-Large 4 and HCC District II runoffs - Houston Chronicle

Early voting opens in Houston’s At-Large 4 and HCC District II runoffs  Houston Chronicle

Early voting opens in Houston’s At-Large 4 and HCC District II runoffs - Houston Chronicle

Click here to get full coverage on Liver scarring before treatment for hepatitis C predicts cancer risk - Liver Disease News

Liver scarring before treatment for hepatitis C predicts cancer risk  Liver Disease News

Liver scarring before treatment for hepatitis C predicts cancer risk - Liver Disease News

Click here to get full coverage on HCC Share Price Plunges To Over Two-Year Low As High Discount Price For Right Issue Spooks Traders - NDTV Profit

HCC Share Price Plunges To Over Two-Year Low As High Discount Price For Right Issue Spooks Traders  NDTV Profit

HCC Share Price Plunges To Over Two-Year Low As High Discount Price For Right Issue Spooks Traders - NDTV Profit

Click here to get full coverage on HCC News Today, Dec 3: Warrior Met Coal Stock Sees Significant Gains - Meyka

HCC News Today, Dec 3: Warrior Met Coal Stock Sees Significant Gains  Meyka

HCC News Today, Dec 3: Warrior Met Coal Stock Sees Significant Gains - Meyka

Click here to get full coverage on HCC shares fall 9% after adjusting to Rs 1,000-crore rights issue: What it means for shareholders - Moneycontrol

HCC shares fall 9% after adjusting to Rs 1,000-crore rights issue: What it means for shareholders  Moneycontrol

HCC shares fall 9% after adjusting to Rs 1,000-crore rights issue: What it means for shareholders - Moneycontrol

Click here to get full coverage on HCC announces All-Conference team - Hamilton County Reporter

HCC announces All-Conference team  Hamilton County Reporter

HCC announces All-Conference team - Hamilton County Reporter

Click here to get full coverage on Atezolizumab Plus Bevacizumab Shows Early TTFS Edge Over TACE in HCC - OncLive

Atezolizumab Plus Bevacizumab Shows Early TTFS Edge Over TACE in HCC  OncLive

Atezolizumab Plus Bevacizumab Shows Early TTFS Edge Over TACE in HCC - OncLive

Click here to get full coverage on J & D Pharmaceuticals LLC Receives Orphan Drug Designation for Treatment of Hepatocellular Carcinoma (HCC) - WV News

J & D Pharmaceuticals LLC Receives Orphan Drug Designation for Treatment of Hepatocellular Carcinoma (HCC)  WV News

J & D Pharmaceuticals LLC Receives Orphan Drug Designation for Treatment of Hepatocellular Carcinoma (HCC) - WV News

Click here to get full coverage on HCC shares crack over 8% on record date for Rs 1,000 crore rights issue - The Economic Times

HCC shares crack over 8% on record date for Rs 1,000 crore rights issue  The Economic Times

HCC shares crack over 8% on record date for Rs 1,000 crore rights issue - The Economic Times

Click here to get full coverage on Why the RxHCC Model Matters More Than You Think - North Penn Now

Why the RxHCC Model Matters More Than You Think  North Penn Now

Why the RxHCC Model Matters More Than You Think - North Penn Now

Click here to get full coverage on Integrative genomics characterizes HCC eRNAs for prognosis and targeted therapy - Nature

Integrative genomics characterizes HCC eRNAs for prognosis and targeted therapy  Nature

Integrative genomics characterizes HCC eRNAs for prognosis and targeted therapy - Nature

Click here to get full coverage on HCC shares jump over 14% as board approves Rs 1,000 crore rights issue; record date & other details - MSN

HCC shares jump over 14% as board approves Rs 1,000 crore rights issue; record date & other details  MSN

HCC shares jump over 14% as board approves Rs 1,000 crore rights issue; record date & other details - MSN

Click here to get full coverage on Why did Hindustan Construction Company shares crash 23% today? Check the reason - Trade Brains

Why did Hindustan Construction Company shares crash 23% today? Check the reason  Trade Brains

Why did Hindustan Construction Company shares crash 23% today? Check the reason - Trade Brains

Click here to get full coverage on HCC Approves ₹1,000 Crore Rights Issue, Shares Fall Over 22% Amid Market Reaction, Full Details Inside - Free Press Journal

HCC Approves ₹1,000 Crore Rights Issue, Shares Fall Over 22% Amid Market Reaction, Full Details Inside  Free Press Journal

HCC Approves ₹1,000 Crore Rights Issue, Shares Fall Over 22% Amid Market Reaction, Full Details Inside - Free Press Journal

Click here to get full coverage on Early voting is underway. Here are our runoff endorsements for key Houston races. | Editorial - Houston Chronicle

Early voting is underway. Here are our runoff endorsements for key Houston races. | Editorial  Houston Chronicle

Early voting is underway. Here are our runoff endorsements for key Houston races. | Editorial - Houston Chronicle

Click here to get full coverage on TRIPLET-HCC at ESMO 2025: Adding Ipilimumab to Atezolizumab–Bevacizumab Fails to Improve Outcomes in Unresectable HCC - Oncodaily

TRIPLET-HCC at ESMO 2025: Adding Ipilimumab to Atezolizumab–Bevacizumab Fails to Improve Outcomes in Unresectable HCC  Oncodaily

TRIPLET-HCC at ESMO 2025: Adding Ipilimumab to Atezolizumab–Bevacizumab Fails to Improve Outcomes in Unresectable HCC - Oncodaily

Click here to get full coverage on HCC Stock Drops 4.93% Ahead Of Record Date For Rs 1,000 Crore Rights Issue - NDTV Profit

HCC Stock Drops 4.93% Ahead Of Record Date For Rs 1,000 Crore Rights Issue  NDTV Profit

HCC Stock Drops 4.93% Ahead Of Record Date For Rs 1,000 Crore Rights Issue - NDTV Profit

Click here to get full coverage on SIERRA Study in ESMO GI 2025: Efficacy of STRIDE in HCC - Oncodaily

SIERRA Study in ESMO GI 2025: Efficacy of STRIDE in HCC  Oncodaily

SIERRA Study in ESMO GI 2025: Efficacy of STRIDE in HCC - Oncodaily

Click here to get full coverage on HCC Share Price Today Down 20% - Equitymaster

HCC Share Price Today Down 20%  Equitymaster

HCC Share Price Today Down 20% - Equitymaster

Click here to get full coverage on Mayo Clinic uses investigational targeted radiopharmaceutical theranostic for hepatocellular carcinoma in first-in-human clinical trial - Mayo Clinic News Network

Mayo Clinic uses investigational targeted radiopharmaceutical theranostic for hepatocellular carcinoma in first-in-human clinical trial  Mayo Clinic News Network

Mayo Clinic uses investigational targeted radiopharmaceutical theranostic for hepatocellular carcinoma in first-in-human clinical trial - Mayo Clinic News Network

Click here to get full coverage on Potential Rays owner considering HCC as stadium site - FOX 13 Tampa Bay

Potential Rays owner considering HCC as stadium site  FOX 13 Tampa Bay

Potential Rays owner considering HCC as stadium site - FOX 13 Tampa Bay

Click here to get full coverage on GPC3-targeted immunoPET allows for early detection of HCC: a pilot clinical study - Journal of Nuclear Medicine

GPC3-targeted immunoPET allows for early detection of HCC: a pilot clinical study  Journal of Nuclear Medicine

GPC3-targeted immunoPET allows for early detection of HCC: a pilot clinical study - Journal of Nuclear Medicine

Click here to get full coverage on The origin of hepatocellular carcinoma depends on metabolic zonation - Science | AAAS

The origin of hepatocellular carcinoma depends on metabolic zonation  Science | AAAS

The origin of hepatocellular carcinoma depends on metabolic zonation - Science | AAAS

Click here to get full coverage on HCC share price: Stock declines up to 23% as scrip turns ex-rights issue; details to consider - Upstox

HCC share price: Stock declines up to 23% as scrip turns ex-rights issue; details to consider  Upstox

HCC share price: Stock declines up to 23% as scrip turns ex-rights issue; details to consider - Upstox

Click here to get full coverage on On-Demand TACE Plus Atezolizumab/Bevacizumab Boosts PFS in Unresectable HCC - OncLive

On-Demand TACE Plus Atezolizumab/Bevacizumab Boosts PFS in Unresectable HCC  OncLive

On-Demand TACE Plus Atezolizumab/Bevacizumab Boosts PFS in Unresectable HCC - OncLive

Click here to get full coverage on Nivolumab/Ipilimumab Establishes Unprecedented Efficacy and Safety Standards in Advanced HCC - OncLive

Nivolumab/Ipilimumab Establishes Unprecedented Efficacy and Safety Standards in Advanced HCC  OncLive

Nivolumab/Ipilimumab Establishes Unprecedented Efficacy and Safety Standards in Advanced HCC - OncLive

Click here to get full coverage on Multi-omic analysis reveals a CAF-stemness-governed classification in HCC liver transplant recipients beyond the Milan criteria - Nature

Multi-omic analysis reveals a CAF-stemness-governed classification in HCC liver transplant recipients beyond the Milan criteria  Nature

Multi-omic analysis reveals a CAF-stemness-governed classification in HCC liver transplant recipients beyond the Milan criteria - Nature

Click here to get full coverage on Irpagratinib Plus Atezolizumab Is Safe and Effective in FGF19+ Advanced HCC - OncLive

Irpagratinib Plus Atezolizumab Is Safe and Effective in FGF19+ Advanced HCC  OncLive

Irpagratinib Plus Atezolizumab Is Safe and Effective in FGF19+ Advanced HCC - OncLive

Click here to get full coverage on The Lancet Commission on hepatocellular carcinoma - The Lancet

The Lancet Commission on hepatocellular carcinoma  The Lancet

The Lancet Commission on hepatocellular carcinoma - The Lancet

Click here to get full coverage on Tokio Marine HCC modernizes catastrophe modeling with Moody’s Risk Modeler™ - Moody's

Tokio Marine HCC modernizes catastrophe modeling with Moody’s Risk Modeler™  Moody's

Tokio Marine HCC modernizes catastrophe modeling with Moody’s Risk Modeler™ - Moody's

Click here to get full coverage on HCC Share Price Surges 14% After Rights Issue Record Date Announcement - Meyka

HCC Share Price Surges 14% After Rights Issue Record Date Announcement  Meyka

HCC Share Price Surges 14% After Rights Issue Record Date Announcement - Meyka

Click here to get full coverage on CircSMEK1 Suppresses HCC via the hnRNPK-IGF2-AKT Axis: A Diagnostic Biomarker and Therapeutic Target - Wiley

CircSMEK1 Suppresses HCC via the hnRNPK-IGF2-AKT Axis: A Diagnostic Biomarker and Therapeutic Target  Wiley

CircSMEK1 Suppresses HCC via the hnRNPK-IGF2-AKT Axis: A Diagnostic Biomarker and Therapeutic Target - Wiley

Click here to get full coverage on HCC share price soars over 14% as board approves ₹1,000 crore rights issue; check record date and other details - livemint.com

HCC share price soars over 14% as board approves ₹1,000 crore rights issue; check record date and other details  livemint.com

HCC share price soars over 14% as board approves ₹1,000 crore rights issue; check record date and other details - livemint.com

Click here to get full coverage on HCC News Today, Dec 4: Hindustan Construction Shares Surge 75% - Meyka

HCC News Today, Dec 4: Hindustan Construction Shares Surge 75%  Meyka

HCC News Today, Dec 4: Hindustan Construction Shares Surge 75% - Meyka

Click here to get full coverage on HCC shares tank 20% after stock begins trading adjusted for ₹1,000 crore rights issue - CNBC TV18

HCC shares tank 20% after stock begins trading adjusted for ₹1,000 crore rights issue  CNBC TV18

HCC shares tank 20% after stock begins trading adjusted for ₹1,000 crore rights issue - CNBC TV18

Click here to get full coverage on Preliminary Casdozokitug Activity in HCC Supports Further Exploration of IL-27 as a Treatment Target - OncLive

Preliminary Casdozokitug Activity in HCC Supports Further Exploration of IL-27 as a Treatment Target  OncLive

Preliminary Casdozokitug Activity in HCC Supports Further Exploration of IL-27 as a Treatment Target - OncLive

Click here to get full coverage on Tiragolumab Disappoints in Untreated Advanced HCC - Medscape

Tiragolumab Disappoints in Untreated Advanced HCC  Medscape

Tiragolumab Disappoints in Untreated Advanced HCC - Medscape

Click here to get full coverage on Fitch Assigns 'AAAsf' Ratings to Hyundaicard Funding XVIII's Notes; Outlook Stable - TradingView

Fitch Assigns 'AAAsf' Ratings to Hyundaicard Funding XVIII's Notes; Outlook Stable  TradingView

Fitch Assigns 'AAAsf' Ratings to Hyundaicard Funding XVIII's Notes; Outlook Stable - TradingView

Click here to get full coverage on HCC Share Price Surge 10% on £100M Rights Issue at £12.50 Per Share - HDFC Sky

HCC Share Price Surge 10% on £100M Rights Issue at £12.50 Per Share  HDFC Sky

HCC Share Price Surge 10% on £100M Rights Issue at £12.50 Per Share - HDFC Sky

Click here to get full coverage on Decoding the molecular and genomic landscape of hepatocellular carcinoma: biomarker discovery, classification frameworks, and therapeutic targeting - Nature

Decoding the molecular and genomic landscape of hepatocellular carcinoma: biomarker discovery, classification frameworks, and therapeutic targeting  Nature

Decoding the molecular and genomic landscape of hepatocellular carcinoma: biomarker discovery, classification frameworks, and therapeutic targeting - Nature

Click here to get full coverage on HCC changing name to ‘Houston City College’ in rebrand projected to cost $2.8 million - Houston Public Media

HCC changing name to ‘Houston City College’ in rebrand projected to cost $2.8 million  Houston Public Media

HCC changing name to ‘Houston City College’ in rebrand projected to cost $2.8 million - Houston Public Media

Click here to get full coverage on FDA Approves Y-90 Resin Microspheres for Unresectable HCC - OncLive

FDA Approves Y-90 Resin Microspheres for Unresectable HCC  OncLive

FDA Approves Y-90 Resin Microspheres for Unresectable HCC - OncLive

Click here to get full coverage on HBV reactivation and prognosis after systemic therapy in HCC with undetectable HBV DNA: a multicenter retrospective study - Nature

HBV reactivation and prognosis after systemic therapy in HCC with undetectable HBV DNA: a multicenter retrospective study  Nature

HBV reactivation and prognosis after systemic therapy in HCC with undetectable HBV DNA: a multicenter retrospective study - Nature

Click here to get full coverage on TACE Plus SBRT Effective in Large Tumors Caused by HCC - AJMC

TACE Plus SBRT Effective in Large Tumors Caused by HCC  AJMC

TACE Plus SBRT Effective in Large Tumors Caused by HCC - AJMC

Click here to get full coverage on ROWAN Study of TheraSphere with Durvalumab and Tremelimumab in HCC Completed Enrollment - Oncodaily

ROWAN Study of TheraSphere with Durvalumab and Tremelimumab in HCC Completed Enrollment  Oncodaily

ROWAN Study of TheraSphere with Durvalumab and Tremelimumab in HCC Completed Enrollment - Oncodaily

Click here to get full coverage on The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment - The Lancet

The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment  The Lancet

The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment - The Lancet

Click here to get full coverage on Noninvasive prognostic classification of ITH in HCC with multi-omics insights and therapeutic implications - Science | AAAS

Noninvasive prognostic classification of ITH in HCC with multi-omics insights and therapeutic implications  Science | AAAS

Noninvasive prognostic classification of ITH in HCC with multi-omics insights and therapeutic implications - Science | AAAS

Click here to get full coverage on Tegavivint Demonstrates Preliminary Antitumor Activity, Safety in Advanced HCC - OncLive

Tegavivint Demonstrates Preliminary Antitumor Activity, Safety in Advanced HCC  OncLive

Tegavivint Demonstrates Preliminary Antitumor Activity, Safety in Advanced HCC - OncLive

Click here to get full coverage on HCC name change: Houston Community College's Board of Trustees votes to rebrand the school as Houston City College - ABC13 Houston

HCC name change: Houston Community College's Board of Trustees votes to rebrand the school as Houston City College  ABC13 Houston

HCC name change: Houston Community College's Board of Trustees votes to rebrand the school as Houston City College - ABC13 Houston

Click here to get full coverage on Nivolumab Plus Ipilimumab Receives EC Approval for First-Line Unresectable HCC - OncLive

Nivolumab Plus Ipilimumab Receives EC Approval for First-Line Unresectable HCC  OncLive

Nivolumab Plus Ipilimumab Receives EC Approval for First-Line Unresectable HCC - OncLive

Click here to get full coverage on AI enhanced diagnostic accuracy and workload reduction in hepatocellular carcinoma screening | npj Digital Medicine - Nature

AI enhanced diagnostic accuracy and workload reduction in hepatocellular carcinoma screening | npj Digital Medicine  Nature

AI enhanced diagnostic accuracy and workload reduction in hepatocellular carcinoma screening | npj Digital Medicine - Nature

Click here to get full coverage on Advanced HCC: Which First-line Treatment Is Best? - Medscape

Advanced HCC: Which First-line Treatment Is Best?  Medscape

Advanced HCC: Which First-line Treatment Is Best? - Medscape

Click here to get full coverage on HCC cancels student trip to London, citing fears of Trump immigration crackdown - Houston Landing

HCC cancels student trip to London, citing fears of Trump immigration crackdown  Houston Landing

HCC cancels student trip to London, citing fears of Trump immigration crackdown - Houston Landing

Click here to get full coverage on Help wanted: Many HCC international students scramble for work, but few get it - Houston Landing

Help wanted: Many HCC international students scramble for work, but few get it  Houston Landing

Help wanted: Many HCC international students scramble for work, but few get it - Houston Landing

Click here to get full coverage on Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy - Nature

Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy  Nature

Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy - Nature

Click here to get full coverage on Hepatocellular carcinoma stem cells: the current state of small molecule-based inhibitors - Nature

Hepatocellular carcinoma stem cells: the current state of small molecule-based inhibitors  Nature

Hepatocellular carcinoma stem cells: the current state of small molecule-based inhibitors - Nature

Click here to get full coverage on Hindustan Construction Company (HCC) - Construction Week India

Hindustan Construction Company (HCC)  Construction Week India

Hindustan Construction Company (HCC) - Construction Week India

Click here to get full coverage on Past, Present, and Couture: Asian Fashion From the HCC Archive - Asia Society

Past, Present, and Couture: Asian Fashion From the HCC Archive  Asia Society

Past, Present, and Couture: Asian Fashion From the HCC Archive - Asia Society

Click here to get full coverage on TACE Plus Drug Combination Effective in Liver Cancer - National Cancer Institute (.gov)

TACE Plus Drug Combination Effective in Liver Cancer  National Cancer Institute (.gov)

TACE Plus Drug Combination Effective in Liver Cancer - National Cancer Institute (.gov)

Click here to get full coverage on Why HCC Share Price is Rising - Equitymaster

Why HCC Share Price is Rising  Equitymaster

Why HCC Share Price is Rising - Equitymaster

Click here to get full coverage on Top stocks in news: RIL, Tata Power, HCL Tech, ITC Hotels, RailTel, CAMS, Zen Tech, HCC - Business Today

Top stocks in news: RIL, Tata Power, HCL Tech, ITC Hotels, RailTel, CAMS, Zen Tech, HCC  Business Today

Top stocks in news: RIL, Tata Power, HCL Tech, ITC Hotels, RailTel, CAMS, Zen Tech, HCC - Business Today

Click here to get full coverage on HCC Tumor Burden Score Predicts Long-Term Outcomes Following MWA - AJMC

HCC Tumor Burden Score Predicts Long-Term Outcomes Following MWA  AJMC

HCC Tumor Burden Score Predicts Long-Term Outcomes Following MWA - AJMC

Click here to get full coverage on HCC asked 1,800 people about changing the community college’s name. Here’s what they said. - Houston Landing

HCC asked 1,800 people about changing the community college’s name. Here’s what they said.  Houston Landing

HCC asked 1,800 people about changing the community college’s name. Here’s what they said. - Houston Landing

Click here to get full coverage on FDA Grants Breakthrough Designation for EvoLiver in HCC - Targeted Oncology

FDA Grants Breakthrough Designation for EvoLiver in HCC  Targeted Oncology

HCC

Price Chart

Key Statistics

Technicals

About HCC

Latest News

Five county athletes among HCC Athletes of the Year - Hamilton County Reporter

Nina Niu Sanford: Multidisciplinary and International HCC Tumor Board at GI ASCO 2026 - Oncodaily

HCC announces new university transfer agreements - Smoky Mountain News

Advanced Charts

Top Gainers

Top Losers